Cardiac amyloidosis is an increasingly recognized and treatable cause of heart failure and cardiomyopathy. Advances in imaging, biomarkers, and targeted therapies have transformed how this condition is diagnosed and managed, making early recognition more important than ever. Please join us to hear Omar F. Abou-Ezzeddine, M.D.C.M., M.S., at the Lawrence Blacher, M.D., Memorial Lecture, where he will provide a 2026 update on amyloid cardiomyopathy, highlighting current diagnostic strategies, emerging therapies, and practical approaches to patient care.